Shannon sells NPSP 29.82: NPS Pharmaceuticals : Pharma Initiates Phase 2a Study of P795 in Adult Patients with Autosomal Dominant Hypocalcemia (ADH)
Open-label, dose-escalating study to assess safety and tolerability of NPSP795, which is designed to directly address the underlying molecular defect associated with ADH NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering ... ...
58 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home